Literature DB >> 27340324

Asunaprevir.

.   

Abstract

Entities:  

Keywords:  asunaprevir; hepatitis C

Year:  2015        PMID： 27340324      PMCID： PMC4917633          DOI： 10.18773/austprescr.2016.009

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  6 in total

Review 1.  Daclatasvir.

Authors: 
Journal:  Aust Prescr       Date:  2015-10-01

Review 2.  Treating hepatitis C - what's new?

Authors:  Alex J Thompson; Jacinta A Holmes
Journal:  Aust Prescr       Date:  2015-09-18

3.  High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.

Authors:  Lionel Piroth; Hubert Paniez; Anne Marie Taburet; Corine Vincent; Eric Rosenthal; Karine Lacombe; Eric Billaud; David Rey; David Zucman; François Bailly; Jean-Pierre Bronowicki; Mélanie Simony; Alpha Diallo; Jacques Izopet; Jean-Pierre Aboulker; Laurence Meyer; Jean-Michel Molina
Journal:  Clin Infect Dis       Date:  2015-05-14       Impact factor: 9.079

4.  Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

Authors:  Donald Jensen; Kenneth E Sherman; Christophe Hézode; Stanislas Pol; Stefan Zeuzem; Victor de Ledinghen; Albert Tran; Magdy Elkhashab; Ziad H Younes; Marcelo Kugelmas; Stefan Mauss; Gregory Everson; Velimir Luketic; John Vierling; Lawrence Serfaty; Maurizia Brunetto; Jeong Heo; David Bernstein; Fiona McPhee; Delphine Hennicken; Patricia Mendez; Eric Hughes; Stephanie Noviello
Journal:  J Hepatol       Date:  2015-02-19       Impact factor: 25.083

5.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Authors:  Michael Manns; Stanislas Pol; Ira M Jacobson; Patrick Marcellin; Stuart C Gordon; Cheng-Yuan Peng; Ting-Tsung Chang; Gregory T Everson; Jeong Heo; Guido Gerken; Boris Yoffe; William J Towner; Marc Bourliere; Sophie Metivier; Chi-Jen Chu; William Sievert; Jean-Pierre Bronowicki; Dominique Thabut; Youn-Jae Lee; Jia-Horng Kao; Fiona McPhee; Justin Kopit; Patricia Mendez; Misti Linaberry; Eric Hughes; Stephanie Noviello
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

6.  Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Authors:  Hiromitsu Kumada; Yoshiyuki Suzuki; Kenji Ikeda; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Akio Ido; Kazuhide Yamamoto; Koichi Takaguchi; Namiki Izumi; Kazuhiko Koike; Tetsuo Takehara; Norifumi Kawada; Michio Sata; Hidetaka Miyagoshi; Timothy Eley; Fiona McPhee; Andrew Damokosh; Hiroki Ishikawa; Eric Hughes
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.